Biotech Breakthrough: Oncolytics’ Promising Cancer Therapy Sparks Interest Amid Executive Vacuum
Oncolytics Biotech Inc. faces financial challenges, reporting a Q4 2024 net loss of $8 million and declining cash reserves. The company’s flagship oncolytic virus, pelareorep, shows promise in cancer therapeutics,…